Fig. 3
From: SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer
Kaplan–Meier survival curves comparing the high and low expression of SLC7A7 in different types of cancer in PrognoScan (a–h). a Survival curves for disease-specific survival (DSS) in one multiple myeloma cohort (GSE2658, n = 559). b–d High SLC7A7 expression was correlated with poor OS in the prostate cancer cohort (GSE16560, n = 281), poor disease-free survival (DFS) in the colorectal cancer cohort (GSE17536, n = 145) and poor OS in the glioma cohort (GSE4412, n = 74). e High SLC7A7 expression was correlated with better DMFS in one breast cancer cohort (GSE19615, n = 115). f High SLC7A7 expression was correlated with better RFS in one breast cancer cohort (GSE1456, n = 159). g, h High SLC7A7 expression was correlated with poor OS and RFS in the lung cancer cohort (GSE31210, n = 204)